Slide 1: Exchange filing cover letter for Investors Presentation
RPG LIFE SCIENCES LIMITED L Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071 , India Tel: +91-22-25292152-55 Fax: +91 -22-25297 423 RPti LIFE SCIENCES October 29, 2021 The Manager BSE Limited Listing Department Corporate Relationship Department Floor National Stoc
Slide 2: Investors' Presentation H1 FY22
RPG LIFE SCIENCES An <>>>R~G Company Investors’ Presentation H1 FY22
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Life Sciences Overview
RPG Life Sciences Overview RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Leader in Immunosuppressants Domestic Formulations
Slide 5: RPG Life Sciences Product Portfolio
RPG Life Sciences Product Portfolio Key Therapies Key Products Immunosuppressant Portfolio Text Book Brands New Portfolio Specialty Chronic Life Cycle Management • Nephrology Azoran· (Existing Products) • Rheumatology Azoran· Azathioprine Domestic Azathioprine Azoran® 15 Trastuzumab • Oncology Azath
Slide 6: Key Financials, Business Highlights & Strategy
Key Financials, Business Highlights & Strategy An <l>» RPCi Company 5 L R?G LIFE SCIENCES
Slide 7: Key Highlights of H1 FY22
Key Highlights of H1 FY22 RPGLS growing faster than the market at 20.4% vs 15.2% (IPM)* Healthy double-digit growth in revenues from operations Profit margins’ record-setting trajectory continues – EBITDA margin reaches 23% & PBT margin 19% H1 records significant PBT margin expansion across the segm
Slide 8: In H1 FY22, Profit Margins' Record-setting Trajectory continues
In H1 FY22, Profit Margins’ Record-setting Trajectory continues… EBITDA% 23% PBT% 18% 19% 16% 14% 11% 10% 10% 10% 9% 9% 8% 6% 6% 6% 5% 5% 4% 1% 0% 0% 0% 7 An <l>» RPCi Company - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - R,ac; LIFE sc1ENcEs
Slide 9: Key Financials: H1 FY22
Key Financials : H1 FY22 (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin - --t - --t - -t 220.8 49.9 41.6 188.8 36.5 27.6 19% 23% 15% 19% FY21 H1 FY22 H1 FY21 H1 FY22 H1 FY21 H1 FY22 H1 PAT & PAT Margin EPS - -t -t 17.7 29.3 12.2 20.2 11%
Slide 10: Key Financials' Trends
Key Financials’ Trends (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin - --t - --t - -t 70.8 53.6 375.6 389.1 59.9 330.2 41.8 41.6 49.9 220.8 34.4 15.1 FY19 FY20 FY21 FY22 H1 □ 10% FY19 16% FY20 18% FY21 23% FY22 H1 lJ5% FY19 11% FY20 14%
Slide 11: Key Financials' Trends
Key Financials’ Trends _f ROCE% _f ROE% Debt/Equity Ratio - -l 23.6% 24.3% 16.4% 18.5% 0.22 11.0% 6.7% 0.06 0.01 FY19 FY20 FY21 FY19 FY20 FY21 FY19 FY20 FY21 Company becomes Debt-free An <l>» RPCi Company 10 L R?G LIFE SCIENCES
Slide 12: Business Segment-wise Performance: H1 FY22
Business Segment-wise Performance : H1 FY22 Sales (Rs Crs) • Domestic Formulations contributed 65% to total Sales of H1 FY22 144.3 Domestic • 21% Sales growth majorly driven by Legacy Products Formulations • Better than Market growth despite Covid headwinds due to second wave 119.7 • New Products Co
Slide 13: Key Financials: Q2 FY22
Key Financials : Q2 FY22 (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin - --t - --t - -t 26.5 22.4 112.7 97.1 19.2 14.7 JY 20% 24% 15% 20% FY21 Q2 FY22 Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 Q2 PAT & PAT Margin EPS - -t -t 9.5 15.8 11.2 6.7 12%
Slide 14: RPG Life Sciences ICRA Rating Upgraded in FY21
RPG Life Sciences ICRA Rating Upgraded in FY21 Long term rating upgraded to A from A- Short term rating upgraded to A1 from A2+ Outlook on long term rating has been retained as Stable. The rating upgradation factors: Considerable improvement in the operating performance on the back of • Improvemen
Slide 15: Domestic Formulations (DF)
Domestic Formulations (DF) • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leader in Immunosuppressant category • Good Customer Coverage - Cardiologists,
Slide 16: International Formulations (IF)
International Formulations (IF) • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and business relationship with some of the
Slide 17: APIs
APIs • High Value, Low Volume Niche APIs • Mature Stable Molecules • Provides backward integration to International Formulations business • Footprints across geographies - LATAM, Iran, Germany, China, South Korea, Bangladesh, Egypt, India, etc • Strong customer focus - Long lasting relationship with
Slide 18: Infrastructure & Backend Capabilities
Infrastructure & Backend Capabilities An <l>» RPCi Company 17 L R?G LIFE SCIENCES
Slide 19: Manufacturing Facilities
Manufacturing Facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the Domestic and Emerging Markets • Multipurpose plant with dedicated product lines for Oral Dosage forms including Tablets, Liquids and Powder • WHO, Kenya, Nigeria approved Formulations Unit 2, Ankleshwar • F2 unit caters
Slide 20: Strong Backend Capabilities
Strong Backend Capabilities 9 - • • Quality All Critical SOPs harmonized through CQA Quarterly Internal audit of all plants by CQA @- • Regulatory Well established & evolved Regulatory function catering to Canada, UK, EU, Australia and Emerging markets • All critical deviations, change controls and
Slide 21: Operational Highlights
Operational Highlights An <l>» RPCi Company 20 L R?G LIFE SCIENCES
Slide 22: RPG Life Sciences response to COVID-19
RPG Life Sciences response to COVID-19 A passionate call to the entire organization to go all out to ensure continuous availability of our life saving, critical medicines to our patients. Our Plants did not stop even for a single day. Every patient, who asked for our critical medicines, serviced by
Slide 23: New Digitalization Initiatives to Transform Business
New Digitalization Initiatives to Transform Business Game Changer Customer Connect Initiative Employee Connect Initiatives Digital Platform for comprehensive ~ 2 .0 Salesforce Operations tracking: #Customer visits, customer engagement activities, sales performance analytics etc .- • Anytime, Anywher
Slide 24: People Initiatives to build Performance Culture with focus on Happiness
People Initiatives to build Performance Culture with focus on Happiness I Love My Work I Feel Valued I am Growing RPGLS Heroes Outperformance We Skill. You Grow. You Excel. We Applaud. Recognition Competency Building Motivation Continuum Continuum •• Akanksha 0 Career Development High Happiness I Li
Slide 25: FY22 Priorities
FY22 Priorities Ensure 100% double dose vaccination of employees Maintain growth momentum in top-line and bottom-line across the business segments Continue to grow our presence in chronic and specialty therapies in DF through new product launches and new customer segments Continue to build iconic/le
Slide 26: Awards & Recognitions
Awards & Recognitions An <l>» RPCi Company 25 L R?G LIFE SCIENCES
Slide 27: RPG Life Sciences Bagged Top Awards from IDMA
RPG Life Sciences Bagged Top Awards from IDMA Prestigious Awards from IDMA - Indian Drug Manufacturer’s Association in January 2020 (consists of 1000+ pharma companies) IDMA Quality Excellence IDMA Corporate Citizen Award 2019 Award 2019 (GOLD AWARD) IDMA Margi Patel Choksi Memorial An <l>» RPCi Com
Slide 28: RPG Life Sciences is one of India's Best Workplaces in 2020
RPG Life Sciences is one of the India’s Best Workplace in 2020 – Amongst Top 100 • Ranked 85 amongst India's 100 Best Companies to Work For 2020 • One of India's Best Workplaces in Biotechnology & Pharmaceuticals by Great Place to Work® Institute Best Workplaces"' 0 I in Biotechnology & Pharm ace
Slide 29: Media Recognition
Media Recognition • Not a single day Plant stoppage • Home Delivery of critical life saving medicines to all the patients pQRTfOU O Pf ' ' dard moneycontrol Business Stan ( 11 ic areas ft Coronavirus Markets v News v Portfolio Commodities Mutual Funds v Personal Finance v Forum v Media v Earth360 In
Slide 30: Thank You
T H A N K Y O U An <l>» RPCi Company L R?G LIFE SCIENCES